Largest Study to Date Links Glucose Control to COVID-19 Outc
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Type 2 diabetes (T2D) is a major comorbidity of COVID-19. However, the impact of blood glucose (BG) control on the degree of required medical interventions and on mortality in patients with COVID-19 and T2D remains uncertain. Thus, researchers performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing T2D.

They found that subjects with T2D required more medical interventions and had a significantly higher mortality (7.8% versus 2.7%) and multiple organ injury than the non-diabetic individuals. Those with diabetes were also significantly more likely to develop acute respiratory distress syndrome, acute kidney injury, and septic shock. Further, they found that well-controlled BG (glycemic variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality compared to individuals with poorly controlled BG during hospitalization. These findings provide clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D.

In conclusion, T2D is an important risk factor for COVID-19 progression and adverse endpoints, and well-controlled BG, maintaining glycemic variability within 3.9 to 10.0 mmol/L, is associated with a significant reduction in the composite adverse outcomes and death. These findings provide critical insights into the clinical characteristics of patients with COVID-19 and pre-existing T2D and the possible avenues to improving their disease outcomes.

Source: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30238-2
Like
Comment
Share